103 related articles for article (PubMed ID: 9253807)
1. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery.
Humphries J; Lattimer C; Smith A; McGuinness CL; Whitton C; Gaffney PJ; Burnand KG
Thromb Res; 1997 Jul; 87(1):123-9. PubMed ID: 9253807
[TBL] [Abstract][Full Text] [Related]
2. The effect of anticoagulation with subcutaneously delivered polyethylene glycol conjugated hirudin and recombinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model.
Alexander B; Burnand KG; Lattimer CL; Humphries J; Gaffney PJ; Eastham D; Smith A
Thromb Res; 2004; 113(2):155-61. PubMed ID: 15115671
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous infusion of r-hirudin does not inhibit neointimal proliferation after angioplasty of the subclavian artery in cholesterol-fed rabbits.
Hadoke PW; Wadsworth RM; Wainwright CL; Butler KD; Giddings MJ
Coron Artery Dis; 1996 Aug; 7(8):599-608. PubMed ID: 8922888
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
7. [Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study].
Schiele F; Vuillemenot A; Mouhat T; Kramarz P; Kieffer Y; Camez A; Bassand JP
Arch Mal Coeur Vaiss; 1995 Mar; 88(3):329-35. PubMed ID: 7487286
[TBL] [Abstract][Full Text] [Related]
8. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
[TBL] [Abstract][Full Text] [Related]
11. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Martin U; Dörge L; Fischer S
Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (clivarine) and polyethyleneglycol-hirudin.
Buchwald AB; Hammerschmidt S; Stevens J; Göring J; Nebendahl K; Unterberg C
J Cardiovasc Pharmacol; 1996 Oct; 28(4):481-7. PubMed ID: 8891870
[TBL] [Abstract][Full Text] [Related]
13. Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
Zeymer U; von Essen R; Tebbe U; Niederer W; Mäurer W; Vogt A; Neuhaus KL
Am J Cardiol; 1995 Nov; 76(14):997-1001. PubMed ID: 7484879
[TBL] [Abstract][Full Text] [Related]
14. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
Witt W; Maass B; Baldus B; Hildebrand M; Donner P; Schleuning WD
Circulation; 1994 Jul; 90(1):421-6. PubMed ID: 8026028
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits.
Sarembock IJ; Gertz SD; Gimple LW; Owen RM; Powers ER; Roberts WC
Circulation; 1991 Jul; 84(1):232-43. PubMed ID: 1829399
[TBL] [Abstract][Full Text] [Related]
16. Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor.
Friederich PW; Keller TT; Biemond BJ; Peters RJ; Hornberger W; Büller HR; Levi M
Thromb Haemost; 2000 Nov; 84(5):858-64. PubMed ID: 11127868
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.
Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G
Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081
[TBL] [Abstract][Full Text] [Related]
18. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
19. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits.
Zawilska K; Zozulinska M; Turowiecka Z; Blahut M; Drobnik L; Vinazzer H
Thromb Res; 1993 Feb; 69(3):315-20. PubMed ID: 8475480
[TBL] [Abstract][Full Text] [Related]
20. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
